Provided by Tiger Fintech (Singapore) Pte. Ltd.

Teva Pharmaceutical

14.87
+0.15001.02%
Post-market: 14.920.0480+0.32%19:48 EDT
Volume:6.57M
Turnover:97.09M
Market Cap:17.06B
PE:-10.26
High:14.90
Open:14.65
Low:14.52
Close:14.72
Loading ...

Teva Pharmaceutical’s Strategic Focus on EBITDA Growth and Cost Efficiencies Drives Buy Rating

TIPRANKS
·
24 Apr

Teva call volume above normal and directionally bullish

TIPRANKS
·
21 Apr

Teva Pharmaceutical Industries (TEVA): Among the Top Healthcare Stocks to Buy According to Billionaire David Einhorn

Insider Monkey
·
12 Apr

Teva Pharmaceutical Industries (NYSE:TEVA) Pops As FDA Expands AJOVY'S Use For Pediatric Migraine Prevention

Simply Wall St.
·
10 Apr

Teva put volume heavy and directionally bearish

TIPRANKS
·
09 Apr

Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory

Insider Monkey
·
08 Apr

BRIEF-Biosimilar Epysqli® (Eculizumab-Aagh) Injection Now Available In The United States

Reuters
·
07 Apr

Teva Rolls Out Lower-Cost Soliris Biosimilar in US

MT Newswires Live
·
07 Apr

Teva, Samsung Bioepis announce EPYSQLI availability in the U.S.

TIPRANKS
·
07 Apr

Teva Pharmaceutical Industries Says US FDA Accepted its sBLA Filing for AJOVY

MT Newswires Live
·
07 Apr

Teva Pharmaceutical Industries Ltd - Epysqli Available at 30% Discount to Soliris Wac

THOMSON REUTERS
·
07 Apr

Teva and Samsung Bioepis Announce Biosimilar Epysqli® (Eculizumab-Aagh) Injection NOW Available in the United States

THOMSON REUTERS
·
07 Apr

Teva and Samsung Bioepis Announce Biosimilar EPYSQLI® (eculizumab-aagh) Injection Now Available in the United States

GlobeNewswire
·
07 Apr

Teva announces FDA acceptance of sBLA for AJOVY

TIPRANKS
·
07 Apr

Top Stock Reports for Cisco, Caterpillar & CME

Zacks
·
04 Apr

Teva Pharmaceuticals : UBS Cuts Target Price to $24 From $27

THOMSON REUTERS
·
01 Apr

Teva Says Schizophrenia Trial Survey Results Show Patient Satisfaction With TEV-'749

MT Newswires Live
·
01 Apr

Teva announces presentation of survey study on TEV-‘749

TIPRANKS
·
01 Apr

Teva Pharmaceutical's Upcoming Cost-Optimization Plan May Offer Significant Benefits, UBS Says

MT Newswires Live
·
31 Mar

Piper Sandler Keeps Their Buy Rating on Teva Pharmaceutical (TEVA)

TIPRANKS
·
31 Mar